Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
Even with signs that the biotech winter may be starting to thaw, buysiders continue to expect more near-term pain for th... Read more
12 Jul 2022
•
23mins
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
AstraZeneca’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholder... Read more
6 Jul 2022
•
29mins
Similar Podcasts
The Readout Loud
The Long Run with Luke Timmerman
Biotech 2050 Podcast
FYI - For Your Innovation
Masters in Business
Business Of Biotech
Odd Lots
Goldman Sachs Exchanges
The Bio Report
Barron's Streetwise
Infinite Loops
a16z Podcast
Barron's Live
The Ezra Klein Show
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
On the latest BioCentury This Week podcast, a pair of deals demonstrates how Galapagos CEO Paul Stoffels is shifting the... Read more
28 Jun 2022
•
25mins
Ep. 125 - Next Steps for ARPA-H
Ep. 125 - Next Steps for ARPA-H
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin details how the Advanced Research Projects Age... Read more
21 Jun 2022
•
24mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
Stellar data for Vertex Pharmaceuticals and CRISPR Therapeutics could set a high bar for the next generation of gene edi... Read more
13 Jun 2022
•
27mins
Ep. 123 - Fixing FDA's Broken Advisory Panels
Ep. 123 - Fixing FDA's Broken Advisory Panels
8 Jun 2022
•
20mins
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
Stellar ASCO data for Enhertu show how there’s “massive ground” that can still be covered and improved upon by applying... Read more
7 Jun 2022
•
26mins
Ep. 121 - ASCO, CRISPR IP & CStone
Ep. 121 - ASCO, CRISPR IP & CStone
The latest data cut for KRAS G12C inhibitor adagrasib from Mirati Therapeutics underwhelmed investors. On the latest Bio... Read more
1 Jun 2022
•
22mins
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
On the latest BioCentury This Week podcast, BioCentury’s editors explore how biotechs are turning to tumor targeting, IL... Read more
23 May 2022
•
21mins
Ep. 119 - Bio€quity Recap, Part 2
Ep. 119 - Bio€quity Recap, Part 2
Ensuring that a biotech reaches its key inflection points as effectively as possible during the ongoing capital crunch a... Read more
19 May 2022
•
20mins
